Skip to main content
. 2021 Jun 15;44(9):1938–1947. doi: 10.2337/dc21-0027

Table 3.

Cox regression models of predictors of glycemic worsening (an absolute increase of 0.5% in HbA1c) in adults

M12 hazard ratio† Lower CI Upper CI P value M21 hazard ratio† Lower CI Upper CI P value
Treatment group 0.089 0.233
 G-MET vs. LIRA+MET 1.32 0.22 7.90 0.763 1.35 0.58 3.12 0.485
 G-MET vs. MET 0.49 0.12 2.04 0.325 1.03 0.47 2.27 0.939
 G-MET vs. placebo 0.27 0.07 1.01 0.051 0.61 0.30 1.25 0.179
 LIRA+MET vs. MET 0.37 0.07 1.91 0.234 0.77 0.32 1.87 0.551
 LIRA+MET vs. placebo 0.21 0.05 0.96 0.044 0.46 0.20 1.02 0.057
 MET vs. placebo 0.56 0.19 1.67 0.296 0.60 0.28 1.27 0.181
Sex (male vs. female) 1.96 0.69 5.53 0.207 1.75 0.95 3.25 0.074
Race/ethnicity
 White vs. other 1.04 0.42 2.58 0.925 1.04 0.60 1.81 0.893
 Black vs. other 0.75 0.27 2.09 0.581 0.95 0.52 1.73 0.870
 Hispanic vs. other 1.68 0.48 5.88 0.418 0.89 0.32 2.51 0.831
Baseline continuous measures
 Age (years) 0.78 0.51 1.18 0.239 1.11 0.82 1.49 0.514
 BMI (kg/m2) 1.03 0.64 1.66 0.915 0.80 0.59 1.08 0.150
 HbA1c (%) 1.05 0.66 1.65 0.842 0.94 0.70 1.27 0.695
 Fasting glucose (mg/dL) 1.21 0.81 1.81 0.356 1.03 0.80 1.33 0.827
 2-h glucose (mg/dL) 1.09 0.68 1.76 0.714 1.21 0.92 1.60 0.179
 Log M/I 0.59 0.39 0.91 0.016 0.67 0.52 0.88 0.0034
 Log ACPRg 0.49 0.29 0.85 0.010 0.67 0.49 0.91 0.011
 Log AIRg 0.47 0.30 0.75 0.001 0.68 0.52 0.90 0.007
 Log SSC-P 0.89 0.49 1.61 0.691 0.86 0.59 1.24 0.415
 Log ACPRmax 0.94 0.59 1.48 0.778 0.90 0.68 1.20 0.476
 Log AIRmax 0.82 0.51 1.33 0.426 0.79 0.59 1.05 0.108
 Log 1/FI 0.57 0.37 0.87 0.010 0.75 0.57 0.97 0.029
 IGI 0.49 0.22 1.08 0.078 0.65 0.43 0.97 0.034
 CPI 0.60 0.31 1.15 0.122 0.72 0.51 1.02 0.062

Bold P values are statistically significant (P < 0.05). All models included a term for treatment arm. CI, 95% confidence interval.

†

Per 1 SD deviation for continuous measures. Treatment arm is adjusted for insulin sensitivity by M/I, clamp-derived β-cell function responses are adjusted for treatment arm and insulin sensitivity by M/I, and all OGTT-derived β-cell function responses are adjusted for treatment arm and Insulin sensitivity by 1/FI.